Abstract
The objective of the present study is to evaluate the cytotoxic activity of Cuminum cyminum Linn ethanolic extract using in-vitro study. Following seven human cancer cell lines Colon 502713, Colo-205, Hep-2, A-549, OVCAR-5, PC-5, SF-295 were taken. The anti-cancer properties of cumin seed was determined using SRB assay. Activity was found to be 25%, 61%, 40%, 31%, 31%, 28%, 27% against SF-295, Colon 502713, Colo-205, Hep-2, A-549, OVCAR-5, PC-5 human cancer cell lines respectively. Cuminum cyminum Linn extract showed 61% maximum activity against Colon 502713 cell line. only 15 species (belonging to ten genera and nine families) have been utilized in cancer chemotherapy at a clinical level, whereas the rest of the identified species are either active against cancer cell lines or exhibit chemotherapeutic properties on tumor-bearing animals under experimental conditions. The outlook of phytochemistry based cancer therapy is discussed, particularly in the perspective of identifying immunomodulatory anti-cancer agents with minimal toxicity on healthy tissues Cuminum cyminum Linn. belongs to the family Umbelliferae. The common English name is Cumin. It is native of Mediterranean region. In India, it is cultivated mainly in the Punjab and Uttar Pradesh. The plant is a short annual herb with small pinkish flowers. The elongated oval fruit are aromatic and light brown in colour. The fruit is a good source of thymol; it is stomachic, diuretic, carminative, stimulant and astringent. It is prescribed in dyspepsia, diarrhea and hoarseness of voice. It is given for promoting secretion of milk. We studied this plant for possible anti-cancer activity using SRB assay against seven human cancer cell lines.
Highlights
Cancer is a major cause of death and the number of new cases, as well as the number of individuals living with cancer, is expanding continuously
Though significant progress has been made towards the characterization of isolated compounds and their structure-related activities, the complex composition of plant extracts, along with the lack of reproducibility of activity and the synergy between different, even unidentified, components of an extract, prohibits the full utilization of plants in pharmaceutical research
Only 15 species have been utilized in cancer chemotherapy at a clinical level, whereas the rest of the identified species are either active against cancer cell lines or exhibit chemotherapeutic properties on tumor-bearing animals under experimental conditions
Summary
Cancer is a major cause of death and the number of new cases, as well as the number of individuals living with cancer, is expanding continuously. Due to the enormous diversity of plants that synthesize mixtures of structurally different bioactive compounds, the plant kingdom is potentially a very diverse source of chemical constituents with tumor cytotoxic activity. Despite the successful utilization of few phytochemicals, such as vincristine and taxol, into mainstream of cancer chemotherapy, commercial plant-derived anti-cancer formulations represent only one-fourth of the total repertoire of the available treatment options. A total of 187 plant species, belonging to 102 genera and 61 families have been identified as an active or promising source of phytochemicals with antitumor properties, corresponding to a 41 percent increase during the last five years. Only 15 species (belonging to ten genera and nine families) have been utilized in cancer chemotherapy at a clinical level, whereas the rest of the identified species are either active against cancer cell lines or exhibit chemotherapeutic properties on tumor-bearing animals under experimental conditions. The outlook of phytochemistry based cancer therapy is discussed, in the perspective of identifying immunomodulatory anti-cancer agents with minimal toxicity on healthy tissues
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
